Latest Financial Position News

Jervois Global Limited has initiated a prepackaged Chapter 11 recapitalisation process in the US, leading to the suspension of its shares on multiple exchanges. Shareholders are being notified with detailed documentation as the company seeks to restructure its finances.

Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.

Infinity Lithium reports steady progress on its San José Lithium Project with updated mining licence requirements and a strategic pivot to new European funding opportunities.

Strategic Energy Resources has completed a significant 25-hole drill program at its Achilles 1 Prospect, confirming widespread polymetallic mineralisation, while a new electromagnetic survey at its Mundi Project reveals promising conductors for further exploration.

Waratah Minerals has reported significant progress in its Spur Gold-Copper Project, extending gold zones with over 4,700 metres drilled in the December quarter. Strategic board appointments signal a new phase for the company as it positions itself for further exploration success.

CurveBeam AI Limited reported a remarkable 150% increase in device purchase orders in Q2 FY25, driven by strong demand for its HiRise™M platform and a new commercial agreement with Stryker. The company is advancing validation of its Enhanced HiRise™ for robotic surgical systems, despite a regulatory delay for its BMD SaaS module.

Nelson Resources bolstered its balance sheet with a $2.3 million placement and appointed Dr Louis Bucci as Executive Director, setting the stage for renewed exploration at its Fortnum and Yarri gold projects in early 2025.

Algorae Pharmaceuticals reports robust progress in its drug development pipeline, highlighted by promising preclinical results for cardiovascular and dementia candidates and significant AI platform enhancements.

Actinogen Medical accelerates recruitment in its pivotal XanaMIA Alzheimer's trial while securing a strong cash position of $22.9 million, underpinning its late-stage development and commercial readiness.

Microba Life Sciences reported a robust Q2 FY25 with revenue more than doubling year-on-year, driven by strong sales of its MetaXplore microbiome test in Australia and promising early adoption in the UK.

Babylon Pump & Power Ltd reports robust H1 FY25 results with $1.8M positive operating cash flow and $3.0M EBITDA, overcoming nickel sector challenges. The company eyes growth through new projects and acquisitions.

Syntara Limited has reported encouraging interim Phase 2 trial results for its lead drug candidate SNT-5505 in myelofibrosis, alongside a successful A$15 million capital raise to advance multiple clinical programs.